DPP4 and type 2 diabetes mellitus: Optimistically, DPP-IV inhibitors can be used to increase the lifetime of incretins by reducing DPP-IV activity, and DPP-IV has been regarded as the prime drug target to treat and prevent type 2 diabetes [2].